drugset / Trial / NCT04337437
Clinical Study of Genakumab for Injection in Chinese Healthy Volunteers
Phase 1
Unknown
40 enrolled
Changchun GeneScience Pharmaceutical Co., Ltd.
Peking Union Medical College Hospital · collab
RandomizedParallel-groupDouble-blindOther
Summary
To evaluate the safety and tolerability of single subcutaneous injection of Genakumab for Injection in Chinese healthy adult volunteers
Timeline
- Start
- 2019-04-22
- Primary completion
- 2020-09
- Completion
- 2020-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Genakumab | Monoclonal antibody | 0.3 mg/kg | Subcutaneous |
| Subject | Genakumab | Monoclonal antibody | 1 mg/kg | Subcutaneous |
| Subject | Genakumab | Monoclonal antibody | 2 mg/kg | Subcutaneous |
| Subject | Genakumab | Monoclonal antibody | 4 mg/kg | Subcutaneous |
| Subject | Genakumab | Monoclonal antibody | 6 mg/kg | Subcutaneous |